News
The agency previously declined to approve Atara's first Ebvallo biologics license application, but has accepted a data package it resubmitted this month.
AstraZeneca Readies for Tagrisso Competition in First-Line Advanced Lung Cancer as Q2 Revenues Surge
The impact of Tagrisso plus chemo on overall survival in a Phase III trial has boosted the firms' confidence to parry competitors.
As Keytruda generic competition looms larger on the horizon, the company is hoping to reinvest the savings into pipeline growth drivers.
The firm will retain rights to its preclinical assets including two T-cell receptor T-cell therapies and its allogenic program.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results